Trial Profile
A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naive HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2022
Price :
$35
*
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ANDES
- 02 Aug 2022 Results from final results (first step/second step) at week 48 are presented at the 24th International AIDS Conference
- 01 Aug 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2018 Primary endpoint (Percentage of patients with HIV-1 RNA levels of less than 50 copies/mL at week 48: non-inferiority of DRV/RTV plus 3TC with standard of care triple drug regimen with ritonavir-bosted Darunavir in FDC plus TDF/3TC) has been met, according to results of week 48, presented at the 25th Conference on Retroviruses and Opportunistic Infections.